Brokers Set Expectations for Vertex Pharmaceuticals Incorporated’s Q3 2025 Earnings (NASDAQ:VRTX)

Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) – Equities research analysts at Zacks Research cut their Q3 2025 EPS estimates for shares of Vertex Pharmaceuticals in a research report issued to clients and investors on Friday, April 19th. Zacks Research analyst R. Department now expects that the pharmaceutical company will post earnings of $3.74 per share for the quarter, down from their previous estimate of $3.75. The consensus estimate for Vertex Pharmaceuticals’ current full-year earnings is $14.95 per share. Zacks Research also issued estimates for Vertex Pharmaceuticals’ Q1 2026 earnings at $3.77 EPS.

Vertex Pharmaceuticals (NASDAQ:VRTX) last announced its earnings results on Monday, February 5th. The pharmaceutical company reported $4.20 earnings per share for the quarter, beating the consensus estimate of $3.85 by $0.35. Vertex Pharmaceuticals had a net margin of 36.68% and a return on equity of 21.91%. The firm had revenue of $2.52 billion during the quarter, compared to the consensus estimate of $2.50 billion. During the same quarter in the previous year, the company posted $3.33 EPS.

A number of other research firms also recently commented on VRTX. Truist Financial upped their price objective on shares of Vertex Pharmaceuticals from $456.00 to $508.00 and gave the company a “buy” rating in a research note on Wednesday, January 31st. Canaccord Genuity Group downgraded shares of Vertex Pharmaceuticals from a “hold” rating to a “sell” rating and increased their target price for the stock from $332.00 to $379.00 in a research report on Wednesday, January 24th. Royal Bank of Canada increased their target price on shares of Vertex Pharmaceuticals from $397.00 to $420.00 and gave the stock a “sector perform” rating in a research report on Tuesday, February 6th. JPMorgan Chase & Co. upped their price target on Vertex Pharmaceuticals from $390.00 to $438.00 and gave the stock an “overweight” rating in a report on Thursday, February 1st. Finally, William Blair restated an “outperform” rating on shares of Vertex Pharmaceuticals in a report on Tuesday, February 6th. Three investment analysts have rated the stock with a sell rating, six have assigned a hold rating and fifteen have given a buy rating to the company’s stock. Based on data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $429.45.

Vertex Pharmaceuticals Trading Up 1.2 %

Shares of VRTX stock opened at $404.91 on Monday. The firm has a 50-day moving average price of $413.00 and a 200 day moving average price of $398.36. Vertex Pharmaceuticals has a twelve month low of $316.43 and a twelve month high of $448.40. The company has a market capitalization of $104.65 billion, a price-to-earnings ratio of 29.15, a PEG ratio of 1.86 and a beta of 0.35. The company has a current ratio of 3.99, a quick ratio of 3.78 and a debt-to-equity ratio of 0.02.

Insider Activity

In other news, EVP Ourania Tatsis sold 354 shares of the stock in a transaction that occurred on Monday, February 26th. The stock was sold at an average price of $425.70, for a total transaction of $150,697.80. Following the completion of the transaction, the executive vice president now directly owns 55,804 shares in the company, valued at approximately $23,755,762.80. The transaction was disclosed in a document filed with the SEC, which is accessible through this link. In related news, EVP Amit Sachdev sold 3,222 shares of the firm’s stock in a transaction on Monday, February 12th. The stock was sold at an average price of $420.24, for a total transaction of $1,354,013.28. Following the transaction, the executive vice president now directly owns 74,364 shares in the company, valued at $31,250,727.36. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, EVP Ourania Tatsis sold 354 shares of the firm’s stock in a transaction on Monday, February 26th. The stock was sold at an average price of $425.70, for a total value of $150,697.80. Following the transaction, the executive vice president now owns 55,804 shares in the company, valued at $23,755,762.80. The disclosure for this sale can be found here. In the last three months, insiders sold 12,381 shares of company stock worth $5,203,249. 0.20% of the stock is currently owned by insiders.

Hedge Funds Weigh In On Vertex Pharmaceuticals

Several large investors have recently added to or reduced their stakes in VRTX. CWM LLC lifted its stake in Vertex Pharmaceuticals by 17.6% during the third quarter. CWM LLC now owns 5,375 shares of the pharmaceutical company’s stock worth $1,869,000 after purchasing an additional 806 shares during the last quarter. Geneos Wealth Management Inc. increased its position in Vertex Pharmaceuticals by 39.4% in the third quarter. Geneos Wealth Management Inc. now owns 191 shares of the pharmaceutical company’s stock worth $66,000 after buying an additional 54 shares during the period. Global Retirement Partners LLC increased its position in Vertex Pharmaceuticals by 28.4% in the third quarter. Global Retirement Partners LLC now owns 1,194 shares of the pharmaceutical company’s stock worth $421,000 after buying an additional 264 shares during the period. HB Wealth Management LLC increased its position in Vertex Pharmaceuticals by 48.2% in the third quarter. HB Wealth Management LLC now owns 3,626 shares of the pharmaceutical company’s stock worth $1,261,000 after buying an additional 1,180 shares during the period. Finally, First Affirmative Financial Network increased its position in Vertex Pharmaceuticals by 21.9% in the third quarter. First Affirmative Financial Network now owns 736 shares of the pharmaceutical company’s stock worth $256,000 after buying an additional 132 shares during the period. 90.96% of the stock is currently owned by institutional investors.

Vertex Pharmaceuticals Company Profile

Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis (CF). It markets TRIKAFTA/KAFTRIO for people with CF with at least one F508del mutation for 2 years of age or older; SYMDEKO/SYMKEVI for people with CF for 6 years of age or older; ORKAMBI for CF patients 1 year or older; and KALYDECO for the treatment of patients with 1 year or older who have CF with ivacaftor.